Apel­lis' eye dis­ease drug gets safe­ty la­bel up­date for rare in­flam­ma­tion side ef­fect

The FDA and Apel­lis Phar­ma­ceu­ti­cals have up­dat­ed the la­bel for Syfovre — an in­jec­tion for late-stage wet age-re­lat­ed mac­u­lar de­gen­er­a­tion — to ad­dress the po­ten­tial risk of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.